This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.